Development History of AAS Stanozolol for bodybuilders

Stanozolol is a popular AAS used by bodybuilders, but its development has not been smooth.

Stanozolol development

In 1962, Stanozolol was listed in the United States by Winthrop(Sterling) under the trade name “Winstrol” and in Europe by Winthrop partner Bayer under the trade name “Stromba”.

In 1970, the FDA classified Stanozolol as potentially effective as an adjunct therapy for elderly and postmenopausal osteoporosis, as well as pituitary dwarfism, and as lacking substantial evidence of effectiveness for several other indications.

The FDA gave Sterling six months to stop marketing Stanozolol for indications for which there is no evidence of efficacy and one year to develop further data for two indications for which it may be effective.

In August and September 1970, Sterling submitted additional data; The FDA deemed the data inadequate but allowed the drug to remain on the market because of an unmet need for osteoporosis and pituitary dwarfism, but Sterling needed to produce more data.

In 1980, the FDA removed the dwarf indication from Stanozolol’s label as human growth hormone drugs became available.

In December 1980 and August 1983, Sterling submitted data to the FDA designed to support the effectiveness of Stanozolol in postmenopausal osteoporosis and aplastic anemia.

These data were reviewed at two meetings of the FDA’s Endocrine and Metabolic Drugs Advisory Committee in 1981 and 1983.

In April 1984, the FDA declared the data inadequate.

In 1988, Sterling was acquired by Eastman Kodak for $5.1 billion.

In 1994 Kodak sold Sterling’s drug business to Sanofi for $1.675 billion.

Sanofi, which makes Stanozolol in the United States from Searle, discontinued production of the drug in October 2002.

In 2003, Sanofi sold its Stanozolol business, along with two other drugs, to Ovation Pharmaceuticals. In the meantime, Stanozolol has not been discontinued and is considered a treatment for hereditary angioedema.

In 2009, Lundbeck acquired Ovation.

In 2010, Lundbeck pulled Stanozolol from the U.S. market. No other company has since marketed Stanozolol in the United States, but it is available through combination (custom drug formulations).

From the above development of Stanozolol, we can see that it went through nearly 50 years before it was withdrawn from the US market in 2010. It is an anabolic steroid that has been tested for nearly 50 years. Although it is no longer sold in the United States, it is still available. To this day, Stanozolol keep to be the most commonly used AAS by bodybuilders.